- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01256489
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The closely related disorders, Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS), represent rare but severe hypersensitivity responses to a systemic medication, and cause severe sloughing of the skin and mucous membranes. Approximately half of affected patients experience ocular involvement, which can lead to corneal opacity and vascularization, and in some patients, blindness. Corneal transplantation (corneal allograft) is typically unsuccessful in SJS/TENS, because of chronic inflammation at the ocular surface, leading to corneal neovascularization and opacity, tissue melt, ulceration, and perforation.
The Boston keratoprosthesis, an artificial cornea developed at the Massachusetts Eye and Ear Infirmary (MEEI) over the last 40 years, is an FDA approved device for patients with corneal blindness not amenable to corneal transplantation, and has restored the sight of thousands of such patients, but in SJS/TENS patients remains associated with tissue melts (tissue ulceration), perforation, and ultimately in some, loss of the eye. K-Pro surgery is currently the best option for patients with SJS or TENS and corneal blindness, but these patients also have the worst prognosis after surgery. While the outcomes of these surgeries for patients with SJS or TENS have improved dramatically in the past ten years, they are still unsatisfactory. Remicade® has been used in a small group of patients with SJS or TENS undergoing K-Pro surgery, with one remarkable success. The purpose of this study is to explore this treatment more fully.
For a case report detailing the use of infliximab in one patient, see the following article: Dohlman JG, Foster CS, Dohlman CH. "Boston Keratoprosthesis in Stevens-Johnson Syndrome: A case of using infliximab to prevent tissue necrosis." Digital Journal of Ophthalmology. 2009, Volume 15, Number 1.
Recently developed biologics have dramatically improved functional outcomes and quality of life in patients with autoimmune diseases. One such agent, infliximab, acts by blocking TNF alpha, a protein associated with tissue melting in the cornea, and is increasingly being used for autoimmune eye conditions, in addition to its FDA approved indication for recalcitrant rheumatoid arthritis.
The proposed study will determine the feasibility of combining infliximab with keratoprosthesis surgery, and will closely monitor patients for episodes of corneal melting: the primary outcome of the study.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts Eye and Ear Infirmary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of biopsy proven SJS/TENS with corneal opacity and neovascularization
- Bilateral legal blindness (<20/200 in better eye)
- 18 years of age or older
- Able to provide informed consent
- Sufficiently healthy to undergo infliximab infusions, surgery, and a vigorous postoperative follow-up course
- Able to administer eye medications or have a care giver able and willing to do same
Are considered eligible according to the following tuberculosis (TB) screening criteria:
- Have no history of latent or active TB prior to screening.
- Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- Have had no recent close contact with a person with active TB.
- Within 6 weeks prior to the first administration of study agent, have a negative QuantiFERON-TB Gold test result (see Attachment A). Indeterminate results should be handled as outlined in the Screening Visit Section. A negative tuberculin skin test is considered acceptable if the QuantiFERON- TB Gold test is not acceptable in that country.
- Have a chest radiograph (posterior-anterior view) taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB.
Exclusion Criteria:
- Visual acuity >20/200 in better eye
- Corneal blindness not due to effects of SJS/TENS
- Hypersensitivity to infliximab or chemically related medication
- Pregnant or lactating
- Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening. Refer to inclusion criteria for information regarding eligibility with a history of latent TB.
- Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
- Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including TB.
- Have had a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, pneumocystosis, aspergillosis) within 6 months prior to screening.
- Have indeterminate initial and repeat QuantiFERON-TB Gold test results.
- History or current diagnosis of diabetes mellitus
- History of immune system problem other than Stevens Johnson Syndrome
- History of recurrent infections
- History or current diagnosis of cancer
- Active psoriasis
- History of heart failure
- History of hepatitis B virus
- MRSA or VRE infection
- Nervous system disorders such as multiple sclerosis or Guillain-Barre syndrome
- Scheduled to receive a live vaccine at any time point during study participation
- Currently receiving treatments of Kineret (Anakinra)
- Unable to attend postoperative visits or administer medications, or no care giver available and willing to assist with same
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Infliximab
Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study.
Infliximab will be administered intravenously.
|
The drug will be administered intravenously every month for 110 weeks (duration of the study).
The initial dose of infliximab will be 5mg/kg of body weight.
The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of corneal ulceration
Time Frame: Assessed monthly for up to 2 years following surgery
|
Assessed monthly for up to 2 years following surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of systemic adverse events
Time Frame: Assessed monthly for up to 2 years following first infusion
|
Assessed monthly for up to 2 years following first infusion
|
Period Of Prosthesis Retention
Time Frame: Assessed monthly for up to 2 years following surgery
|
Assessed monthly for up to 2 years following surgery
|
Vision Recovery
Time Frame: Assessed monthly for up to 2 years following surgery
|
Assessed monthly for up to 2 years following surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: James Chodosh, MD, MPH, Massachusetts Eye and Ear Infirmary
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Eye Diseases
- Neurologic Manifestations
- Disease
- Stomatognathic Diseases
- Mouth Diseases
- Hypersensitivity
- Erythema
- Skin Diseases, Vesiculobullous
- Dermatitis
- Sensation Disorders
- Drug-Related Side Effects and Adverse Reactions
- Vision Disorders
- Stomatitis
- Drug Eruptions
- Erythema Multiforme
- Drug Hypersensitivity
- Syndrome
- Stevens-Johnson Syndrome
- Blindness
- Antirheumatic Agents
- Gastrointestinal Agents
- Dermatologic Agents
- Infliximab
Other Study ID Numbers
- 10-02-010
- 196405 (Other Identifier: MEEI Human Studies Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stevens-Johnson Syndrome
-
University of LiegeCompleted
-
Centre Hospitalier Universitaire VaudoisCompletedStevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
-
Singapore National Eye CentreNational Medical Research Council (NMRC), Singapore; Singapore Eye Research... and other collaboratorsCompletedPterygium | Ocular Surface Disease | Chemical Injury | Stevens Johnson SyndromeSingapore
-
Seoul National University HospitalMinistry of Health & Welfare, KoreaAvailableLimbal Stem Cell Deficiency | Ocular Cicatricial Pemphigoid | Stevens-johnson Syndrome | Chemical BurnKorea, Republic of
-
Joseph B. Ciolino, MDCompletedAutoimmune Diseases | Rheumatoid Arthritis | Lupus Erythematosus, Systemic | Ocular Cicatricial Pemphigoid | Stevens Johnson Syndrome | Chemical Injuries | Unspecified Complication of Corneal Transplant | Other Autoimmune DiseasesUnited States
-
Nihon Pharmaceutical Co., LtdCompletedStevens-Johnson Syndrome | Toxic Epidermal NecrolysisJapan
-
University of PernambucoCompleted
-
Chulalongkorn UniversityMahidol University; Chiang Mai University; Phramongkutklao College of Medicine... and other collaboratorsUnknownDrug Reaction With Eosinophilia and Systemic Symptoms | Toxic Epidermal Necrolysis | Acute Generalized Exanthematous Pustulosis | Steven-Johnson Syndrome | Generalized Bullous Fixed Drug EruptionThailand
-
National Taiwan University HospitalUnknownChronic Graft Versus Host Disease | Sjogren Syndrome | Mucous Membrane Pemphigoid | Cicatrizing Conjunctivitis | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | Chemical Burn to EyeTaiwan
-
University of California, DavisWithdrawnToxic Epidermal NecrolysisUnited States
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
PfizerCompleted
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
European Organisation for Research and Treatment...CompletedMyelodysplastic SyndromesFrance, Belgium, Netherlands, Czech Republic, Italy, Germany
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus